Odyssey Therapeutics secured a valuation of $899.9 million after its shares rose 11.1% in their Nasdaq debut on Friday, ...
Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
Investor's Business Daily on MSN
Why these four biotech stocks prove that follow-on entries still pop up in stock market leaders
AnaptysBio recorded $234 million in sales over the past four quarters.
Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout ...
Per documents filed with the Securities and Exchange Commission, Ideaya and landlord DW LSP 5000 Shoreline LLC executed a ...
The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...
Sara Ahmed ’26, a student in the MBA for Executives program, drew on her background in biotech to craft a speaker series ...
May 7 (Reuters) - Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results